Abstract
Bombesin (BBN) is a peptide exhibiting high affinity for the gastrin-releasing peptide receptor (GRPR), which is overexpressed on several types of cancers. Various GRPR antagonists and agonists have been labeled with radiometals for positron emission tomography (PET) imaging of GRPR-positive tumors. However, unfavorable hepatobiliary excretion such as high intestinal activity may prohibit their clinical utility for imaging abdominal cancer. In this study, the modified BBN peptide with a new hydrophilic linker was labeled with 68Ga for PET imaging of GRPR-expressing PC-3 prostate cancer xenograft model. GRPR antagonists, MATBBN (Gly-Gly-Gly-Arg-Asp-Asn-d-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-NHCH2CH3) and ATBBN (d-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-NHCH2CH3), were conjugated with 1,4,7-triazacyclononanetriacetic acid (NOTA) and labeled with 68Ga. Partition coefficient and in vitro stability were also determined. GRPR binding affinity of both tracers was investigated by competitive radioligand binding assay. The in vivo receptor targeting potential and pharmacokinetic of 68Ga-NOTA-MATBBN were also evaluated in PC-3 prostate tumor model and compared with those of 68Ga-NOTA-ATBBN. NOTA-conjugated BBN analogs were labeled with 68Ga within 20 min with a decay-corrected yield ranging from 90 to 95 % and a radiochemical purity of more than 98 %. The specific activity of 68Ga-NOTA-MATBBN and 68Ga-NOTA-ATBBN was at least 16.5 and 11.9 GBq/μmol, respectively. The radiotracers were stable in phosphate-buffered saline and human serum. 68Ga-NOTA-MATBBN was more hydrophilic than 68Ga-NOTA-ATBBN, as indicated by their log P values (−2.73 ± 0.02 vs. −1.20 ± 0.03). The IC50 values of NOTA-ATBBN and NOTA-MATBBN were similar (102.7 ± 1.18 and 124.6 ± 1.21 nM). The accumulation of 68Ga-labeled GRPR antagonists in the subcutaneous PC-3 tumors could be visualized via small animal PET. The tumors were clearly visible, and the tumor uptakes of 68Ga-NOTA-MATBBN and 68Ga-NOTA-ATBBN were determined to be 4.19 ± 0.32, 4.00 ± 0.41, 2.93 ± 0.35 and 4.70 ± 0.40, 4.10 ± 0.30, 3.14 ± 0.30 %ID/g at 30, 60, and 120 min, respectively. There was considerable accumulation and retention of 68Ga-NOTA-ATBBN in the liver and intestines. In contrast, the abdominal area does not have much retention of 68Ga-NOTA-MATBBN. Biodistribution data were in accordance with the PET results, showing that 68Ga-NOTA-MATBBN had more favorable pharmacokinetics and higher tumor to background ratios than those of 68Ga-NOTA-ATBBN. At 1 h postinjection, the tumor to liver and intestine of 68Ga-NOTA-MATBBN were 8.05 ± 0.56 and 21.72 ± 3.47 and the corresponding values of unmodified counterpart were 0.85 ± 0.23 and 3.45 ± 0.43, respectively. GRPR binding specificity was demonstrated by reduced tumor uptake of radiolabeled tracers after coinjection of an excess of unlabeled BBN peptides. 68Ga-NOTA-MATBBN exhibited GRPR-targeting properties both in vitro and in vivo. The favorable characterizations of 68Ga-NOTA-MATBBN such as convenient synthesis, specific GRPR targeting, high tumor uptake, and satisfactory pharmacokinetics warrant its further investigation for clinical cancer imaging.
Similar content being viewed by others
References
Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR (2011a) Radiopeptide imaging and therapy in Europe. J Nucl Med 52(Suppl 2):42S–55S
Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR (2011b) Radiopeptide imaging and therapy in Europe. J Nucl Med 52:42S–55S
Ananias HJ, Yu Z, Dierckx RA, van der Wiele C, Helfrich W, Wang F, Yan Y, Chen X, de Jong IJ, Elsinga PH (2011) (99 m)technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model. Mol Pharm 8(4):1165–1173. doi:10.1021/mp200014h
Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ et al (2011) (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med 41:314–321
Carroll RE, Ostrovskiy D, Lee S, Danilkovich A, Benya RV (2000) Characterization of gastrin-releasing peptide and its receptor aberrantly expressed by human colon cancer cell lines. Mol Pharmacol 58:601–607
Chen X, Park R, Hou Y, Tohme M, Shahinian AH et al (2004) MicroPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 45:1390–1397
de Sá A, Matias AA, Prata MI, Geraldes CF, Ferreira PM et al (2010) Gallium labeled NOTA-based conjugates for peptide receptor-mediated medical imaging. Bioorgan Med Chem Lett 20:7345–7348
Dijkgraaf I, Franssen GM, McBride WJ, D’Souza CA, Laverman P et al (2012) PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog. J Nucl Med 53:947–952
Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Mäcke HR, Eisenhut M, Strauss LG (2007) 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J Nucl Med 48(8):1245–1250
Dumont RA, Tamma M, Braun F, Borkowski S, Reubi JC, Maecke H, Weber WA, Mansi R (2013) Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med 54:762–769
Fani M, Andre JP, Maecke HR (2008) 68 Ga-PET: a powerful generator based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging 3:67–77
Fleischmann A, Waser B, Gebbers JO, Reubi JC (2005) Gastrin-releasing peptide receptors in normal and neoplastic human uterus: involvement of multiple tissue compartments. J Clin Endocrinol Metab 90:4722–4729
Graham MM, Menda Y (2011) Radiopeptide imaging and therapy in the United States. J Nucl Med 52(Suppl 2):56S–63S
Hoffman TJ, Gali H, Smith CJ, Sieckman GL, Hayes DL, Owen NK et al (2003) Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 44:823–831
Lang L, Li W, Guo N, Ma Y, Zhu L et al (2011) Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem 22(12):2415–2422
Laverman P, Sosabowski JK, Boerman OC, Oyen WJ (2012) Radiolabelled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging 39:S78–S92
Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R et al (2011) In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med 52:470–477
Liu Z, Yan Y, Chin FT, Wang F, Chen X (2012) Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem 18:11079–11087
Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR (2011) Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 38(1):97–107
Nanda PK, Pandey U, Bottenus BN, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Smith CJ (2012) Bombesin analogues for gastrin-releasing peptide receptor imaging. Nucl Med Biol 39(4):461–471
Reubi JC, Korner M, Waser B, Mazzucchelli L, Guillou L (2004) High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 31:803–810
Reubi JC, Macke HR, Krenning EP (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46:67S–75S
Roivainen A, Kähkönen E, Luoto P, Borkowski S, Hofmann B, Jambor I, Lehtiö K, Rantala T, Rottmann A, Sipilä H, Sparks R, Suilamo S, Tolvanen T, Valencia R, Minn H (2013) Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68 Ga bombesin antagonist BAY86-7548 in healthy men. J Nucl Med 54:867–872
Sancho V, Di Florio A, Moody TW, Jensen RT (2011) Bombesin receptor-mediated imaging and cytotoxicity: review and current status. Curr Drug Deliv 8:79–134
Schuhmacher J, Zhang H, Doll J, Mäcke HR, Matys R et al (2005) GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68 Ga-labeled bombesin (6–14) analog. J Nucl Med 46:691–699
Yang M, Gao HK, Zhou YR, Ma Y, Quan QM et al (2011) 18F-labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging. Theranostics 1:220–229
Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu JC et al (2006) 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 47:492–501
Acknowledgments
This work was partially supported by National Natural Science Foundation (81171399 and 81101077), CSC Foundation (2011832173), National Significant New Drugs Creation Program (2012ZX09505-001-001), Jiangsu Province Science and Technology Foundation (BE2012622, BK2011166 and BL2012031), Health Ministry of Jiangsu Province Fund (RC2011095 and H201028), Public Service Platform for Science and Technology Infrastructure Construction Project of Jiangsu Province (BM2012066), and University of Wisconsin-Madison Department of Medical Physics and Department of Radiology (Radiology R&D Award 1105-002).
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Pan, D., Xu, Y.P., Yang, R.H. et al. A new 68Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging. Amino Acids 46, 1481–1489 (2014). https://doi.org/10.1007/s00726-014-1718-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-014-1718-y